Courtney Hathaway, MD
Family Medicine · Missoula, MTNPI 1326484130
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 58 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by AbbVie at 31.7% of the total. Reporting peaked in 2019 at $416 and has fallen 95.5% since, to $19 in 2025.
Across 58 payments — averaging $15.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$283
- AstraZeneca$70
- Novo Nordisk$60
- Lilly USA, LLC$48
- Pfizer$47
- Amgen$43
- plus $341 from 15 others
What the payments were for
- Food & beverage$892100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 18 | $283 |
| AstraZeneca | 6 | $70 |
| Novo Nordisk | 4 | $60 |
| Lilly USA, LLC | 3 | $48 |
| Pfizer | 4 | $47 |
| Amgen | 2 | $43 |
| Astellas Pharma US Inc | 2 | $40 |
| Shire North American Group Inc | 3 | $39 |
| Corium, LLC | 2 | $35 |
| GSK | 2 | $29 |
| Organon | 1 | $28 |
| Scynexis, Inc. | 1 | $22 |
| Exeltis, USA Inc. | 1 | $22 |
| Roche Diagnostics Corporation | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| Merck | 1 | $13 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
| Johnson & Johnson | 1 | $12 |
| Sanofi Pasteur Inc. | 1 | $12 |
How this compares
$892 in reported general payments places this provider in the 85th percentile of 426 family medicine providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 34 | $46,616 |
| EliquisApixaban | 35 | $30,828 |
| JardianceEmpagliflozin | 35 | $28,170 |
| MounjaroTirzepatide | 22 | $23,378 |
| FarxigaDapagliflozin Propanediol | 15 | $12,181 |
| BelbucaBuprenorphine Hcl | 14 | $9,327 |
| Potassium Chloride | 57 | $8,181 |
| Budesonide | 28 | $4,955 |
| Aripiprazole | 15 | $4,699 |
| Phenobarbital | 19 | $2,738 |
| Fluoxetine Hcl | 34 | $1,879 |
| Fentanyl | 12 | $1,871 |
| Atorvastatin Calcium | 156 | $1,829 |
| Levothyroxine Sodium | 200 | $1,753 |
| Clorazepate Dipotassium | 15 | $1,679 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $60 | $46,61634 claims |
| PfizerEliquis | $47 | $30,82835 claims |
| Lilly USA, LLCMounjaro | $48 | $23,37822 claims |
| AstraZenecaFarxiga | $70 | $12,18115 claims |
| AbbVieSynthroid | $283 | $94912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 426 family medicine providers in Montana.
Other family medicine in Missoula
- Kimberly BlakesleeMissoula$186K
- Joey BanksMissoula$21K
- Aubrey RemmersMissoula$5K
- Eric RavitzMissoula$2K
- Lar AutioMissoula$1K
- Christopher SmithMissoula$1K
- Geoffrey HolmanMissoula$1K
- Carol BridgesMissoula$953
- Kendra LeeMissoula$792
- Sarah BorgeMissoula$777
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.